Posaconazole oral suspension — Competitive Intelligence Brief

Posaconazole oral suspension (Posaconazole oral suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triazole antifungal. Area: Infectious Disease.

phase 3 Triazole antifungal Lanosterol 14α-demethylase (CYP51) Infectious Disease Small molecule

Target snapshot

Posaconazole oral suspension (Posaconazole oral suspension) — Merck Sharp & Dohme LLC. Posaconazole inhibits fungal cell membrane ergosterol synthesis by blocking lanosterol 14α-demethylase, disrupting fungal cell wall integrity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Posaconazole oral suspension TARGET	Posaconazole oral suspension	Merck Sharp & Dohme LLC	phase 3	Triazole antifungal	Lanosterol 14α-demethylase (CYP51)
Posaconazole Delayed Release Oral Tablet	Posaconazole Delayed Release Oral Tablet	Cedars-Sinai Medical Center	marketed	Triazole antifungal	Lanosterol 14α-demethylase (CYP51)
Diflucan (fluconazole)	Diflucan (fluconazole)	Pfizer	marketed	Triazole antifungal	Fungal cytochrome P450 14α-demethylase (CYP51)
fast itraconazole tablet	fast itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
anidulafungin and voriconazole	anidulafungin and voriconazole	Pfizer	marketed	Echinocandin and triazole antifungal combination	β-1,3-glucan synthase (anidulafungin); fungal CYP51/lanosterol 14α-demethylase (voriconazole)
slow itraconazole tablet	slow itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal cytochrome P450 14α-demethylase (CYP51)
Voriconazole clinical practice	Voriconazole clinical practice	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triazole antifungal class)

1. University of Maryland, Baltimore · 3 drugs in this class
2. Manjunath Prakash Pai · 2 drugs in this class
3. Pfizer · 2 drugs in this class
4. Janssen Pharmaceutical K.K. · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. Seoul National University Hospital · 1 drug in this class
8. University of California, San Francisco · 1 drug in this class
9. University of Minnesota · 1 drug in this class
10. Bayer · 1 drug in this class